{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-124869","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.199551+00:00","generated_at":"2026-06-07T14:40:58.720270+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Marker Therapeutics reports sustained complete response in Phase 1 lymphoma patient at 6 months","bullets":["DLBCL patient who failed anti-CD19 CAR T and 3 prior therapies achieved CR at 8 weeks and remains in CR at 6 months after MT-601.","MT-601 is a multiTAA-specific T cell therapy, non-genetically engineered, well-tolerated without severe CAR T side effects like neurotoxicity.","Up to 60% of lymphoma patients relapse within one year after CAR T; this patient had relapsed within 90 days yet maintained response.","Company has enrolled additional patients in APOLLO study to replicate results; City of Hope is the trial site.","Non-clinical data shows MT-601 can eradicate lymphoma cells resistant to anti-CD19 CAR T in vitro."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-124869","json":"https://secwatch.observer/filing/0001104659-23-124869.json","markdown":"https://secwatch.observer/filing/0001104659-23-124869.md","text":"https://secwatch.observer/filing/0001104659-23-124869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923124869/0001104659-23-124869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923124869/tm2332541d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:40:58.720270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}